Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

MR venography using an intravascular contrast agent: results from a multicenter phase 2 study of dosage.

MR venography using an intravascular contrast agent: results from a multicenter phase 2 study of dosage. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • MR venography using an intravascular contrast agent: results from a multicenter phase 2 study of dosage. Abstract Text:

    elna-marie larssonElna-Marie Larsson,paul sundénPaul Sundén,carl-gustav olssonCarl-Gustav Olsson,jörg debatinJörg Debatin,andre j duerinckxAndre J Duerinckx,richard baumRichard Baum,dietbert hahnDietbert Hahn,franz ebnerFranz Ebner,

    OBJECTIVE: The objective of this study was to determine the optimal dose of the iron oxide contrast agent feruglose for contrast-enhanced MR venography of the abdominopelvic and lower extremity veins and to evaluate its safety and tolerability in patients with deep venous thrombosis. SUBJECTS AND METHODS: We enrolled in our study a total of 45 patients at six centers who had lower extremity deep venous thrombosis documented on radiographic venography. Forty-four patients received the study drug; 39 completed the study. Each patient received three sequential IV injections of feruglose at doses of 0.75, 1.25, and 3.0 mg Fe/kg body weight. MR venography at 1.5 T was repeated at three levels after each dose. Safety was evaluated. RESULTS: The agreement between contrast-enhanced MR venography and radiographic venography with regard to deep venous thrombosis above the knee was zero at the lowest dose (0.75 mg Fe/kg body weight), 43% at the dose 2.0 mg Fe/kg body weight, and 49% at the dose 5.0 mg Fe/kg body weight. No significant difference was seen between the two highest doses. The highest cumulative dose provided the greatest diagnostic usefulness score. No serious adverse events occurred. CONCLUSION: The two highest doses of feruglose showed the best agreement between contrast-enhanced MR venography and radiographic venography for deep venous thrombosis above the knee. The safety and tolerability of feruglose were confirmed.

    MR venography using an intravascular contrast agent: results from a multicenter phase 2 study of dosage. Publishing Authors By Initials

    em larssonEM Larsson,p sundénP Sundén,cg olssonCG Olsson,j debatinJ Debatin,aj duerinckxAJ Duerinckx,r baumR Baum,d hahnD Hahn,f ebnerF Ebner,

    For similar cardiovascular diseases: vascular diseases: embolism and thrombosis: thrombosis: venous thrombosis research abstracts see: cardiovascular diseases: vascular diseases: embolism and thrombosis: thrombosis: venous thrombosis research

    PUBMED ID PMID:

    MEDLINE DATE:

    MR venography using an intravascular contrast agent: results from a multicenter phase 2 study of dosage. Journal Published:

    PUBLICATION TYPE: Research Support, U.S. Gov't,

    Journal: AJR. American journal of roentgenology

    VOLUME: 180

    Page Numbers: 227-32

    Journal Abbreviation:

    ISSN: 0361-803X

    DAY: 15

    MONTH: Jan

    YEAR: 2003

    MR venography using an intravascular contrast agent: results from a multicenter phase 2 study of dosage. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 7708173

    MR venography using an intravascular contrast agent: results from a multicenter phase 2 study of dosage. Keywords Mesh Terms:

    KEYWORDS: Venous Thrombosis

    MESH TERMS: radiography

    Chemical & Substance for Abstract: MR venography using an intravascular contrast agent: results from a multicenter phase 2 study of dosage. Information

    Substance Name: Iron

    Registry Number: 7439-89-6

    Grant and Affiliation Information for MR venography using an intravascular contrast agent: results from a multicenter phase 2 study of dosage.

    AFFILIATION: Department of Neuroradiology, Center for Medical Imaging and Physiology, Lund University Hospital, SE-221 85 Lund, Sweden.

    Country: United States

    United States Research PublicationUnited States Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: AJR Am J Roentgenol

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    MR venography using an intravascular contrast agent: results from a multicenter phase 2 study of dosage Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News